RxDoctor Payments Data

Fernando Pujol-Morato, MD

Internal Medicine · Brooklyn, NYNPI 1043263098

Payments from drug & device makers

$4,346in general payments, 2019–2025

Across 188 payments — averaging $23.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Viiv Healthcare Company$1K
  • Shionogi Inc$814
  • AbbVie$626
  • Gilead$532
  • Melinta Therapeutics, LLC$305
  • Johnson & Johnson$240
  • plus $543 from 5 others

What the payments were for

  • Food & beverage$4,344100%
  • Education$20%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$4,346 in reported general payments places this provider in the 85th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$102,315
Medicare patients
193
Services billed
963

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala107$426,733
Pyrimethamine12$105,305
JulucaDolutegravir/Rilpivirine30$101,956
TivicayDolutegravir Sodium12$49,974
IsentressRaltegravir Potassium24$45,084
DescovyEmtricitabine/Tenofov Alafenam13$28,168
PrezistaDarunavir11$21,068
Emtricitabine-Tenofovir DisopEmtricitabine/Tenofovir (Tdf)32$5,264
MyrbetriqMirabegron11$4,505
Ritonavir20$1,836
Rosuvastatin Calcium28$385
Gabapentin35$288
Omeprazole21$244
Metoprolol Tartrate27$135
Montelukast Sodium12$131

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadBiktarvy, Descovy$532$454,901120 claims
Viiv Healthcare CompanyJuluca, Tivicay$1,286$151,93142 claims
MerckIsentress$227$45,08424 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in Brooklyn

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →